Carcinogenesis, Teratogenesis & Mutagenesis ›› 2019, Vol. 31 ›› Issue (5): 412-416.doi: 10.3969/j.issn.1004-616x.2019.05.014
Previous Articles Next Articles
Received:2019-06-14
Revised:2019-09-26
Online:2019-09-30
Published:2019-10-09
CLC Number:
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| [1] CANCER GENOME ATLAS RESEARCH N, BRAT D J, VERHAAK R G, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas[J]. N Engl J Med, 2015, 372(26):2481-2498. [2] GRAMATZKI D, KICKINGEREDER P, HENTSCHEL B, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma[J]. Neurology, 2017, 88(15):1422-1430. [3] VERHAAK R G, HOADLEY K A, PURDOM E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1[J]. Cancer Cell, 2010, 17(1):98-110. [4] NOUSHMEHR H, WEISENBERGER D J, DIEFES K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma[J]. Cancer Cell, 2010, 17(5):510-522. [5] BHAT K P, SALAZAR K L, BALASUBRAMANIYAN V, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma[J]. Genes Dev, 2011, 25(24):2594-2609. [6] FRATTINI V, TRIFONOV V, CHAN J M, et al. The integrated landscape of driver genomic alterations in glioblastoma[J]. Nat Genet, 2013, 45(10):1141-1149. [7] DANUSSI C, AKAVIA U D, NIOLA F, et al. RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation[J]. Cancer Res, 2013, 73(16):5140-5150. [8] BRENNAN C W, VERHAAK R G, MCKENNA A, et al. The somatic genomic landscape of glioblastoma[J]. Cell, 2013, 155(2):462-477. [9] KRELL D, MULHOLLAND P, FRAMPTON A E, et al. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets[J]. Future Oncol, 2013, 9(12):1923-1935. [10] XU W, YANG H, LIU Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases[J]. Cancer Cell, 2011, 19(1):17-30. [11] GROSS S, CAIRNS R A, MINDEN M D, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations[J]. J Exp Med, 2010, 207(2):339-344. [12] BLEEKER F E, ATAI N A, LAMBA S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma[J]. Acta Neuropathol, 2010, 119(4):487-494. [13] FU X, CHIN R M, VERGNES L, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling[J]. Cell Metab, 2015, 22(3):508-515. [14] TURKALP Z, KARAMCHANDANI J, DAS S. IDH mutation in glioma:new insights and promises for the future[J]. JAMA Neurol, 2014, 71(10):1319-1325. [15] LI H, LI J, CHENG G, et al. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy[J]. Clin Neurol Neurosurg, 2016, 151:31-36. [16] HARTMANN C, HENTSCHEL B, TATAGIBA M, et al. Molecular markers in low-grade gliomas:predictive or prognostic?[J]. Clin Cancer Res, 2011, 17(13):4588-4599. [17] HOUILLIER C, WANG X, KALOSHI G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas[J]. Neurology, 2010, 75(17):1560-1566. [18] HURTT M R, MOOSSY J, DONOVAN-PELUSO M, et al. Amplification of epidermal growth factor receptor gene in gliomas:histopathology and prognosis[J]. J Neuropathol Exp Neurol, 1992, 51(1):84-90. [19] JAROS E, PERRY R H, ADAM L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours[J]. Br J Cancer, 1992, 66(2):373-385. [20] SCHLEGEL J, MERDES A, STUMM G, et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma[J]. Int J Cancer, 1994, 56(1):72-77. [21] EKSTRAND A J, SUGAWA N, JAMES C D, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails[J]. Proc Natl Acad Sci U S A, 1992, 89(10):4309-4313. [22] HEIMBERGER A B, HLATKY R, SUKI D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvⅢ in glioblastoma multiforme patients[J]. Clin Cancer Res, 2005, 11(4):1462-1466. [23] SHINOJIMA N, TADA K, SHIRAISHI S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme[J]. Cancer Res, 2003, 63(20):6962-6970. [24] NARITA Y, NAGANE M, MISHIMA K, et al. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas[J]. Cancer Res, 2002, 62(22):6764-6769. [25] PHILLIPS H S, KHARBANDA S, CHEN R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis[J]. Cancer Cell, 2006, 9(3):157-173. [26] CLARKE I D, DIRKS P B. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming[J]. Oncogene, 2003, 22(5):722-733. [27] OZAWA T, BRENNAN C W, WANG L, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas[J]. Genes Dev, 2010, 24(19):2205-2218. [28] CANCER GENOME ATLAS RESEARCH N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways[J]. Nature, 2008, 455(7216):1061-1068. [29] ASSANAH M, LOCHHEAD R, OGDEN A, et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses[J]. J Neurosci, 2006, 26(25):6781-6790. [30] ASSANAH M C, BRUCE J N, SUZUKI S O, et al. PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain[J]. Glia, 2009, 57(16):1835-1847. [31] PHILPOTT C, TOVELL H, FRAYLING I M, et al. The NF1 somatic mutational landscape in sporadic human cancers[J]. Hum Genomics, 2017, 11(1):13. [32] BANERJEE S, BYRD J N, GIANINO S M, et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo[J]. Cancer Res, 2010, 70(4):1356-1366. [33] TOONEN J A, SOLGA A C, MA Y, et al. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology[J]. J Exp Med, 2017, 214(1):17-25. [34] AMATYA V J, NAUMANN U, WELLER M, et al. TP53 promoter methylation in human gliomas[J]. Acta Neuropathol, 2005, 110(2):178-184. [35] BAEZA N, WELLER M, YONEKAWA Y, et al. PTEN methylation and expression in glioblastomas[J]. Acta Neuropathol, 2003, 106(5):479-485. [36] NAKAMURA M, YONEKAWA Y, KLEIHUES P, et al. Promoter hypermethylation of the RB1 gene in glioblastomas[J]. Lab Invest, 2001, 81(1):77-82. [37] COSTELLO J F, BERGER M S, HUANG H S, et al. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation[J]. Cancer Res, 1996, 56(10):2405-2410. [38] HEGI M E, DISERENS A C, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J]. N Engl J Med, 2005, 352(10):997-1003. [39] WICK W, PLATTEN M, MEISNER C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly:the NOA-08 randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(7):707-715. [40] ESTELLER M, GARCIA-FONCILLAS J, ANDION E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents[J]. N Engl J Med, 2000, 343(19):1350-1354. [41] HEGI M E, DISERENS A C, GODARD S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide[J]. Clin Cancer Res, 2004, 10(6):1871-1874. [42] HERRLINGER U, RIEGER J, KOCH D, et al. Phase Ⅱ trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma:UKT-03[J]. J Clin Oncol, 2006, 24(27):4412-4417. [43] DUCREST A L, SZUTORISZ H, LINGNER J, et al. Regulation of the human telomerase reverse transcriptase gene[J]. Oncogene, 2002, 21(4):541-552. [44] GERTLER R, ROSENBERG R, STRICKER D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma[J]. J Clin Oncol, 2004, 22(10):1807-1814. [45] LU L, ZHANG C, ZHU G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome[J]. Breast Cancer Res, 2011, 13(3):R56. [46] SANDERS R P, DRISSI R, BILLUPS C A, et al. Telomerase expression predicts unfavorable outcome in osteosarcoma[J]. J Clin Oncol, 2004, 22(18):3790-3797. [47] GRIEWANK K G, MURALI R, SCHILLING B, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours[J]. Br J Cancer, 2013, 109(2):497-501. [48] HORN S, FIGL A, RACHAKONDA P S, et al. TERT promoter mutations in familial and sporadic melanoma[J]. Science, 2013, 339(6122):959-961. [49] KILLELA P J, REITMAN Z J, JIAO Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal[J]. Proc Natl Acad Sci U S A, 2013, 110(15):6021-6026. [50] IDERAABDULLAH F Y, VIGNEAU S, BARTOLOMEI M S. Genomic imprinting mechanisms in mammals[J]. Mutat Res, 2008, 647(1-2):77-85. [51] BAYLIN S B, ESTELLER M, ROUNTREE M R, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer[J]. Hum Mol Genet, 2001, 10(7):687-692. [52] TANWAR M K, GILBERT M R, HOLLAND E C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma[J]. Cancer Res, 2002, 62(15):4364-4368. [53] KNOBBE C B, REIFENBERGER J, REIFENBERGER G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas[J]. Acta Neuropathol, 2004, 108(6):467-470. [54] SCHINDLER G, CAPPER D, MEYER J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma[J]. Acta Neuropathol, 2011, 121(3):397-405. [55] KLEINSCHMIDT-DEMASTERS B K, AISNER D L, BIRKS D K, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation[J]. Am J Surg Pathol, 2013, 37(5):685-698. [56] KARAJANNIS M A, LEGAULT G, FISHER M J, et al. Phase Ⅱ study of sorafenib in children with recurrent or progressive low-grade astrocytomas[J]. Neuro Oncol, 2014, 16(10):1408-1416. [57] ROBINSON G W, ORR B A, GAJJAR A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy[J]. BMC Cancer, 2014, 14:258. [58] GUTTMAN M, RINN J L. Modular regulatory principles of large non-coding RNAs[J]. Nature, 2012, 482(7385):339-346. [59] SAHU A, SINGHAL U, CHINNAIYAN A M. Long noncoding RNAs in cancer:from function to translation[J]. Trends Cancer, 2015, 1(2):93-109. [60] KIM S S, HARFORD J B, MOGHE M, et al. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide[J]. Nucleic Acids Res, 2018, 46(3):1424-1440. [61] ZHANG L, WANG Q, WANG F, et al. LncRNA LINC01446 promotes glioblastoma progression by modulating miR-489-3p/TPT1 axis[J]. Biochem Biophys Res Commun, 2018, 503(3):1484-1490. [62] PASTORI C, KAPRANOV P, PENAS C, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation[J]. Proc Natl Acad Sci U S A, 2015, 112(27):8326-8331. |
| [1] | WANG Miao, WANG Quankai, LI Xinwei, MA Shunpeng, WUHAN Baolier, XU Jianning. m6A methylation of mRNAs in glycidyl methacrylate-induced malignant transformation of 16HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 405-409. |
| [2] | GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450. |
| [3] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 470-474. |
| [4] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 475-481. |
| [5] | CUI Zhaoyang, LI Suna, JIANG Xuqian, WANG Yidan, HOU Liying. Activation of the TRAIL death receptor by apigenin for induction of apoptosis in the gastric cancer SGC-7901 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 32-36. |
| [6] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 72-76. |
| [7] | LI Jinglei, HOU Wei. ceRNA network-based stigmasterolintervention on lung squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 423-429. |
| [8] | SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443. |
| [9] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 477-480,484. |
| [10] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 485-489. |
| [11] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 317-320,324. |
| [12] | LUAN Yiran, LIU Liyuan, JIAO Long, WANG Yueling, BAI Hanyu, ZOU Naiyi, MA Ming. Clinical significance of miR-429 and Bmi-1 mRNA expression in diffuse large B-cell lymphoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 177-181. |
| [13] | GULZARIA·Aikula, TAN Yao, PALIDA·Apiziaji. Expression of long non-coding RNAs in esophageal squamous cell carcinoma of Kazak nationality in Xinjiang [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 194-197,202. |
| [14] | SHU Zhixiong, WU Chuancheng, WU Xiaoli, LIU Baoying. Relationships between gastric cancer and SNPs of autophagy-related genes on the PI3K/Akt/mTOR pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(2): 118-125,131. |
| [15] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 67-71. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
